S M Bhavnani

Summary

Affiliation: Ordway Research Institute
Country: USA

Publications

  1. ncbi request reprint Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, NY 14221 5831, USA
    Diagn Microbiol Infect Dis 51:31-7. 2005
  2. ncbi request reprint Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 60:59-64. 2008
  3. pmc Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections
    S M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Blvd, Latham, NY 12110, USA
    Antimicrob Agents Chemother 54:1207-12. 2010
  4. doi request reprint Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Diagn Microbiol Infect Dis 62:99-101. 2008
  5. doi request reprint Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis
    S M Bhavnani
    Institute for Clinical Pharmacodynamics at Ordway Research Institute, Albany, New York, USA
    Clin Infect Dis 49:691-8. 2009
  6. pmc Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, New York, USA
    Antimicrob Agents Chemother 50:994-1000. 2006
  7. pmc Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, NY, USA
    Antimicrob Agents Chemother 49:3944-7. 2005
  8. pmc Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
    J K Thomas
    The Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, Buffalo, New York, USA
    Antimicrob Agents Chemother 42:521-7. 1998
  9. ncbi request reprint Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction
    Paul G Ambrose
    Division of Infectious Diseases, Cognigen Corporation, Buffalo, 395 Youngs Road, Buffalo, NY 14221 5831, USA
    J Antimicrob Chemother 52:435-40. 2003
  10. ncbi request reprint A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia
    S M Bhavnani
    The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital Kaleida Health, Buffalo, New York, USA
    Diagn Microbiol Infect Dis 36:145-58. 2000

Collaborators

Detail Information

Publications42

  1. ncbi request reprint Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, NY 14221 5831, USA
    Diagn Microbiol Infect Dis 51:31-7. 2005
    ..Given the US environment of increasing pneumococcal resistance, these data may be useful in better understanding factors related to emergence of fluoroquinolone resistance...
  2. ncbi request reprint Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 60:59-64. 2008
    ..29). Oral gemifloxacin is clinically effective and has an economic advantage over ceftriaxone, followed by oral cefuroxime with or without a macrolide...
  3. pmc Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections
    S M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Blvd, Latham, NY 12110, USA
    Antimicrob Agents Chemother 54:1207-12. 2010
    ..594. These findings demonstrated the impact of individual and multiple factors on clinical response in the context of drug exposure...
  4. doi request reprint Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Diagn Microbiol Infect Dis 62:99-101. 2008
    ..Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials...
  5. doi request reprint Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis
    S M Bhavnani
    Institute for Clinical Pharmacodynamics at Ordway Research Institute, Albany, New York, USA
    Clin Infect Dis 49:691-8. 2009
    ..The cost-effectiveness (CE) of daptomycin was compared with that of vancomycin-gentamicin in patients with MRSA bacteremia with or without endocarditis...
  6. pmc Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, New York, USA
    Antimicrob Agents Chemother 50:994-1000. 2006
    ..84, P = 0.05, when one patient, a medical outlier, was excluded). A similar relationship was found for clinical response. These results will be valuable in supporting dose selection of oritavancin for patients with S. aureus bacteremia...
  7. pmc Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, NY, USA
    Antimicrob Agents Chemother 49:3944-7. 2005
    ..Simulation results predict that 500 mg of doripenem administered over 1 h every 8 h would be effective against bacterial strains with MICs less than 2 microg/ml and that less susceptible strains could be treated with prolonged infusions...
  8. pmc Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
    J K Thomas
    The Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, Buffalo, New York, USA
    Antimicrob Agents Chemother 42:521-7. 1998
    ..In summary, the selection of antimicrobial resistance appears to be strongly associated with suboptimal antimicrobial exposure, defined as an AUC[0-24]MIC ratio of less than 100...
  9. ncbi request reprint Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction
    Paul G Ambrose
    Division of Infectious Diseases, Cognigen Corporation, Buffalo, 395 Youngs Road, Buffalo, NY 14221 5831, USA
    J Antimicrob Chemother 52:435-40. 2003
    ....
  10. ncbi request reprint A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia
    S M Bhavnani
    The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital Kaleida Health, Buffalo, New York, USA
    Diagn Microbiol Infect Dis 36:145-58. 2000
    ..Results from both LR and CART indicated that patients with persisting enterococcal bacteremia, intubation at baseline, higher APACHE II scores, and VRE bacteremia were at greater risk for poor outcome...
  11. pmc Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables
    Jeffrey P Hammel
    Cognigen Corporation, Buffalo, New York, USA
    Antimicrob Agents Chemother 50:62-7. 2006
    ..5% of cases for the CR approach. When censored MIC data are modeled, CR may reduce or eliminate biased parameter estimates obtained by SR...
  12. ncbi request reprint Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Pharmacotherapy 25:717-40. 2005
    ....
  13. pmc Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi
    Brent M Booker
    The University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Applied Pharmacodynamics Labooratory, New York, USA
    Antimicrob Agents Chemother 49:1775-81. 2005
    ....
  14. pmc Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4085-9. 2007
    ..15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution...
  15. ncbi request reprint Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis
    Paul G Ambrose
    Division of Infectious Diseases, Cognigen Corporation, Buffalo, New York 14221, USA
    Clin Infect Dis 38:1513-20. 2004
    ..88-2.23). For patients infected with pneumococci, the median time to sinus sterilization was 50 h. The use of quantitative time-related end points may be useful in evaluating the efficacy of antimicrobial agents with fewer patients...
  16. doi request reprint Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
    C M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Boulevard, Latham, NY 12110, USA
    Pulm Pharmacol Ther 22:279-85. 2009
    ..Administration of pirfenidone with food has a modest effect on overall exposure but results in lower peak concentrations, which may improve tolerability...
  17. doi request reprint Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis
    Paul G Ambrose
    ICPD Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 61:13-20. 2008
    ..1 (n = 14, %CV = 27). Plasma AUC/MIC ratios ranged from 33.9 to 1696 for isolated pathogens. In this pilot SSAS study, levofloxacin rapidly eradicated isolated pathogens from the maxillary sinus...
  18. ncbi request reprint Back to the future: using aminoglycosides again and how to dose them optimally
    George L Drusano
    Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 45:753-60. 2007
    ..Using these new insights, we suggest ways of evaluating the dose and schedule of administration of aminoglycosides in empirical therapy to obtain the highest likelihood of an efficacious and nontoxic therapy...
  19. pmc Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
    Antimicrob Agents Chemother 53:4422-8. 2009
    ..These results suggest that dose modification may be warranted in patients weighing >110 kg. However, the mild nature of the observed relationships for Vc suggest that dosing adjustments are not necessary for elderly patients...
  20. ncbi request reprint Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 44:79-86. 2007
    ..Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models...
  21. ncbi request reprint Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 54:231-6. 2006
    ..Although infections arising from E. coli and Klebsiella species are associated with significant mortality, ESBL production alone did not appear to be an independent risk factor for treatment failure...
  22. ncbi request reprint Clinical pharmacodynamics of quinolones
    Paul G Ambrose
    Division of Infectious Diseases, Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221, USA
    Infect Dis Clin North Am 17:529-43. 2003
    ..The maturation of antimicrobial PK-PD as a scientific discipline continues to accelerate and currently impacts clinical practice, drug development, and regulatory decision making...
  23. doi request reprint Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York 12110, USA
    Clin Infect Dis 51:S103-10. 2010
    ..Early consideration of these data in development programs will reduce risk not only to sponsors but also, most importantly, to the patients enrolled in the clinical trials...
  24. pmc Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose
    Gerald J Fetterly
    Cognigen Corporation, 395 Youngs Rd, Buffalo, NY 14221 5831, USA
    Antimicrob Agents Chemother 49:148-52. 2005
    ..5-fold at 12 h and 1.5- to 3-fold at 24 h following administration of both dosing regimens. These results support the potential use of oritavancin for the treatment of cSSSI...
  25. doi request reprint Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Latham, NY 12208, USA
    Diagn Microbiol Infect Dis 63:155-9. 2009
    ..25 mg/L. The median probability of microbiologic success was 66% or less for MIC values of 0.5 mg/L or greater. These data support a susceptibility breakpoint of 0.25 mg/L for S. aureus and streptococci...
  26. pmc Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4351-5. 2007
    ..Sensitivity analyses suggest that the probability of PK-PD target attainment in adults and children is not affected by increases in MICs for strains of B. anthracis to levels as high as 0.5 mg/liter...
  27. doi request reprint Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients
    Scott A Van Wart
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Latham, NY 12110, USA
    Diagn Microbiol Infect Dis 63:409-14. 2009
    ....
  28. ncbi request reprint Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, NY, USA
    Diagn Microbiol Infect Dis 50:95-102. 2004
    ..Because this study was not placebo-controlled and enrolled a small number of subjects, the safety and pharmacokinetic profiles of oritavancin need to be confirmed in additional studies...
  29. ncbi request reprint Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, NY 14221 5831, USA
    Clin Infect Dis 37:344-50. 2003
    ..Our findings demonstrate a relationship between MIC and certain patient- and institution-specific variables. Such data should be considered in the design of clinical trials directed at the study of resistant pathogens...
  30. doi request reprint Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York, USA
    Clin Infect Dis 50:1568-74. 2010
    ....
  31. ncbi request reprint Pharmacodynamics in the evaluation of drug regimens
    Sujata M Bhavnani
    Cognigen Corp, Buffalo, NY 14221 5831, USA
    Ann Pharmacother 36:530-2. 2002
    ....
  32. ncbi request reprint Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals
    Sujata M Bhavnani
    Clinical Pharmacokinetics Laboratory CPL, UB, Buffalo, NY, USA
    Am J Health Syst Pharm 60:1962-70. 2003
    ..Increases in expenditures for levofloxacin and ofloxacin were associated with a significant decrease in P. aeruginosa susceptibility to ciprofloxacin...
  33. pmc Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program
    P G Ambrose
    Cognigen Corporation, Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1643-6. 2003
    ..These data suggest that the probability of achieving T>MIC target attainment rates is generally higher with cefepime than with piperacillin-tazobactam for present-day ESBL-producing strains when one uses contemporary dosing regimens...
  34. ncbi request reprint Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model
    Patrick F Smith
    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Applied Pharmacodynamics Laboratory, Department of Pharmacy Practice, Buffalo, NY 14260, USA
    Diagn Microbiol Infect Dis 56:379-86. 2006
    ..influenzae. Consistent with limited clinical data, a minimum %T > MIC of 40% to 50% would be suggested to achieve in vivo activity in otitis media, with maximal activity at approximately 70%T > MIC...
  35. ncbi request reprint Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth
    Tawanda Gumbo
    Emerging Infections and Host Defenses Section, Ordway Research Institute, Albany, NY, USA
    J Infect Dis 195:194-201. 2007
    ..We examined the veracity of this cornerstone belief...
  36. pmc Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection
    Olanrewaju O Okusanya
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
    Antimicrob Agents Chemother 53:3847-54. 2009
    ..Together, these findings likely represent drug effect and warrant the further development of liposomal amikacin for inhalation...
  37. ncbi request reprint The inoculum effect: fact or artifact?
    William A Craig
    Diagn Microbiol Infect Dis 50:229-30. 2004
  38. ncbi request reprint Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae
    Robert C Owens
    Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 51:45-9. 2005
    ..Preferential use of pharmacodynamically potent agents over other alternatives may lead to improved clinical outcomes and decreased selection of fluoroquinolone-resistant pneumococci...
  39. pmc Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 47:292-6. 2003
    ..pneumoniae and that gatifloxacin has an overall 14.3% higher probability of achieving clinically important PK-PD target ratios than levofloxacin...
  40. pmc Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:2329-36. 2007
    ....
  41. doi request reprint Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate
    John S Bradley
    Division of Infectious Diseases, Children s Hospital and Health Center, San Diego, CA 92123, USA
    Pediatr Infect Dis J 27:794-9. 2008
    ..Hospitalized neonates are exposed to antibiotic-resistant bacterial pathogens and develop nosocomial infections. Limited data are available regarding the neonatal pharmacokinetics of meropenem, a broad spectrum carbapenem antibiotic...
  42. pmc Association of fluconazole pharmacodynamics with mortality in patients with candidemia
    John W Baddley
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL 35294 0006, USA
    Antimicrob Agents Chemother 52:3022-8. 2008
    ..In addition, similar MICs were obtained using a 24- or 48-h MIC endpoint determination, thus providing the opportunity to assess earlier the impact of isolate susceptibility on therapy...